Supernus Pharma (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous s...
- Open
- 47.860
- High
- 48.260
- Low
- 46.930
- Prev. Close
- 48.540
- Volume
- 646.85K
- Turnover
- 30.69M
- Avg Price
- 47.448
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 2.74%
- 52wk High
- 59.680
- Volume Ratio
- 1.34
- Turnover Ratio
- 1.25%
Supernus Pharma Analyst Rating
View moreForecast & Rating
Aug 7, 2026Price forecast
$61.7530.14%
Forecast & RatingBuy
4analysts
- Strong buy75.00%
- Buy0.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Aug 17 at 04:19 AM
Indivior Q2 2026 Earnings Call: Complete Transcript
- businessinsider · Aug 9 at 09:59 AM
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and more
- PR Newswire · Aug 7 at 01:16 PM
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
- MorningStar · Aug 7 at 10:38 AM
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Pharmaceutical Technology · Aug 4 at 05:57 AM
Supernus and Indivior merge to create scaled, CNS-focused entity
- benzinga_article · Aug 4 at 05:04 AM
Top 3 Health Care Stocks You'll Regret Missing This Quarter
